|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Overall, these data confirm the important role played by epigenetic events, including BCL6 translocation, p53 expression, and microenvironment components, including macrophage and mast cell infiltration and microvascular density involved in the regulation of breast cancer progression.
|
29854311 |
2018 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Based on the gene network analysis, ESR1, TP53, NCOA1, AKT1, and BCL6 were found to be key genes to demonstrate the molecular mechanisms of EDCs in the development of breast cancer.
|
28973975 |
2017 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The aim of the present study was to investigate the expression of BCL6, zinc finger E-box-binding homeobox (ZEB)1 and ZEB2 and their associations in breast cancer.
|
29104620 |
2017 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Survival analysis with recursive partitioning in node-negative ERα-positive breast cancer using quantitative CK5 and BCL6 mRNA or protein expression data identified patients at high or low risk for tumor recurrence in two independent patient cohorts.
|
26096934 |
2016 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Targeting BCL6 has therapeutic potential against the development and progression of breast cancer.
|
26049022 |
2015 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, targeting BCL6 alone or in conjunction with other signaling pathways may be a useful therapeutic strategy for treating breast cancer.
|
24662818 |
2015 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In vitro, the forced expression of BCL6 results in increased proliferation, anchorage-independent growth, migration, invasion and survival of breast cancer cell lines, whereas knockdown of BCL6 expression reduced these oncogenic properties of breast cancer cells.
|
24917186 |
2014 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The present progress may have direct implications for breast cancer progression and therapy as loss of prolactin receptor-Stat5 signaling occurs frequently and BCL6 inhibitors currently being evaluated for lymphomas may have value for breast cancer.
|
23708665 |
2014 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
From these, we validated and further characterized novel gene fusions involving ROS1 tyrosine kinase in angiosarcoma (CEP85L/ROS1), SLC1A2 glutamate transporter in colon cancer (APIP/SLC1A2), RAF1 kinase in pancreatic cancer (ATG7/RAF1) and anaplastic astrocytoma (BCL6/RAF1), EWSR1 in melanoma (EWSR1/CREM), CDK6 kinase in T-cell acute lymphoblastic leukemia (FAM133B/CDK6), and CLTC in breast cancer (CLTC/VMP1).
|
23637631 |
2013 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Over-expression of miR-127 or depletion of BCL6 inhibits breast cancer cell proliferation.
|
24282530 |
2013 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
BCL6 also plays an important role in breast cancer pathogenesis, a disease in which STAT3 and STAT5 can be activated individually or concomitantly.
|
23716595 |
2013 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prolactin suppression of BCL6 was extended to xenotransplant tumors in nude mice in vivo and to freshly isolated human breast cancer explants ex vivo.
|
20124477 |
2010 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The results strongly suggest the loss of BCL-6 expression in breast cancer progression, which might be related with methylation status alterations of still unknown partner gene(s).
|
19816083 |
2009 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Highly discriminative expression profiles were produced on both simulated gene expression data and expression data from breast cancer and lymphoma datasets on the basis of ER and BCL-6 expression, respectively.
|
17963508 |
2007 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The BCL-6 gene is involved in diffuse large-cell lymphoma and overexpressed in other types of non-Hodgkin's lymphoma and in high-grade breast cancer.
|
16331266 |
2006 |
|
Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Involvement of BCL-6 in breast carcinogenesis is further underscored by comparative genomic hybridization analysis that showed gains at the BCL-6 locus (3q27) in 14/86 (16%) breast cancer tissues.
|
14654791 |
2003 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Consistent with an antiapoptotic function, we demonstrate that BCL-6 is expressed in 68% of histologically high-grade ductal breast carcinomas, which are clinically the most aggressive.
|
12944904 |
2003 |